Publications scientifiques

Publications scientifiques

Azizi M, Courand PY, Denolle T, Delsart P, Zhygalina V, Amar L, Lantelme P, Mounier-Vehier C, De Mota N, Balavoine F, Llorens-Cortes C. A pilot double-blind randomised placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension.

J Hypertens. 2019 Aug;37(8):1722-1728.

doi: 10.1097/HJH.0000000000002092.

EN SAVOIR PLUS

Ferdinand KC, Balavoine F, Besse B, Black HR, Desbrandes S, Dittrich HC, Nesbitt SD. Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins.

Circulation. 2019 Jul 9;140(2):138-146. doi: 10.1161/CIRCULATIONAHA.119.040070.

EN SAVOIR PLUS

Keck M, De Almeida H, Compère D, Inguimbert N, Flahault A, Balavoine F, Roques B, Llorens-Cortes C. NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension.

Hypertension. 2019 Jun;73(6):1300-1307.

doi: 10.1161/HYPERTENSIONAHA.118.12499.

EN SAVOIR PLUS

Keck M, Hmazzou R, Llorens-Cortes C. Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions.

Curr Hypertens Rep. 2019 May 21;21(7):50.

doi: 10.1007/s11906-019-0957-4.

EN SAVOIR PLUS

Boitard SE, Marc Y, Keck M, Mougenot N, Agbulut O, Balavoine F, Llorens-Cortes C. Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice.

J Mol Cell Cardiol. 2019 Feb;127:215-222.

doi: 10.1016/j.yjmcc.2018.12.008

EN SAVOIR PLUS

Leenen FHH., Ahmad M., Marc Y, Llorens-Cortes C. Specific inhibition of brain angiotensin III formation as a new strategy for prevention of heart failure after myocardial infarction.

J Cardiovasc Pharmacol. 2019 Feb;73(2):82-91.

doi: 10.1097/FJC.0000000000000638

EN SAVOIR PLUS

Gao, J., Marc, Y., Iturrioz, X., Leroux, V., Balavoine, F., Llorens-Cortes, C. A new strategy for treating hypertension by blocking the activity of the brain renin-angiotensin system with aminopeptidase A inhibitors.

Clin Sci (Lond). 2014 Aug;127(3):135-48.

doi: 10.1042/CS20130396.

EN SAVOIR PLUS

Balavoine F, Azizi M, Bergerot D, De Mota N, Patouret R, Roques BP, Llorens-Cortes C. (2014) Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally ActingAminopeptidase A Inhibitor Prodrug. Clin Pharmacokinet. doi: 10.1007/ s40262-013-0125-y

EN SAVOIR PLUS

Huang BS, Ahmad M, White RA, Marc Y, Llorens-Cortes C, Leenen FH. (2013) Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction. Cardiovasc Res. 2013;97(3):424-31.

EN SAVOIR PLUS

Marc Y, Gao J, Balavoine F, Michaud A, Roques BP, Llorens-Cortes C. (2012) Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. Hypertension. 2012;60(2):411-8.

EN SAVOIR PLUS

Marc Y, Llorens-Cortes C. The role of the brain renin-angiotensin system in hypertension: implications for new treatment.

Prog Neurobiol. 2011 Oct;95(2):89-103.

doi: 10.1016/j.pneurobio.2011.06.006

EN SAVOIR PLUS

Bodineau L, Frugière A, Marc Y, Inguimbert N, Fassot C, Balavoine F, Roques B, Llorens-Cortes C (2008) Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension. 2008 May;51(5):1318-25.

EN SAVOIR PLUS

Congrès scientifiques

American Heart Association 2018

Ferdinand KC, Balavoine F, Besse B, Black HR, Desbrandes S, Dittrich HC, Nesbitt SD. Efficacy and Safety of a Novel Antihypertensive Pharmacotherapy Approach in a High-Risk Diverse Population

Circulation. 2018;138:e766, December 2018

EN SAVOIR PLUS

European Society of Hypertension 2017

Azizi, M.; Courand, P.; Denolle, T.; Zhygalina, V.; Delsart, P.; Amar, L.; Lantelme, P.; Deplanque, D.; Mounier-Vehier, C.; Balavoine, F.; Madonna, O.; Llorens-Cortes, C. A randomized double-blind placebo controlled crossover study to compare QGC001, a brain aminopeptidase A inhibitor, with placebo in patients with grade I/II essential hypertension.

J Hypertens. 35:e36, September 2017.

EN SAVOIR PLUS

European Society of Hypertension 2016

Hmazzou, R.; Flahault, A.; Marc, Y.; Llorens-Cortes, C. Mode of action of RB150, an aminopeptidase A inhibitor prodrug as a centrally-acting antihypertensive agent in DOCA-salt hypertensive rats.

J Hypertens. 34:e75, September 2016.

EN SAVOIR PLUS

Marc, Y.; Hmazzou, R.; Flahault, A.; Llorens-Cortes, C. Central antihypertensive effects of chronic treatment with RB150/QGC001, an orally active aminopeptidase A inhibitor prodrug in DOCA-salt hypertensive rats.

J Hypertens. 34:e103, September 2016.

EN SAVOIR PLUS

European Society of Hypertension 2014

Balavoine, F., Azizi, M., Bergerot, D., De Mota, N., Patouret, R., Roques, B.P., Llorens-Cortes, C. Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of QGC001, a centrally-acting aminopeptidase A inhibitor, in healthy volunteers.

J Hypertens. 32:e82, September 2014.

EN SAVOIR PLUS

European Society of Hypertension 2013

Balavoine, F., Kousignian, Bergerot, D., De Mota, N., Chassard, D., Segard, L., Roques, B.P., Llorens-Cortes, C., Azizi, M. Safety, tolerability, pharmacokinetics and pharmacodynamics of QGC001, a centrally-acting aminopeptidase A inhibitor, in healthy volunteers.

J Hypertens. 31:e114, September 2013.

EN SAVOIR PLUS